{"entity":{"id":"nct00805376","kind":"trial","name":"DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas","aka":[],"tldr":"A phase 1 trial of DNX-2401 run by DNAtrix, Inc., completed.","summary":"DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas is a phase 1 interventional study registered as NCT00805376 by DNAtrix, Inc., with 37 participants enrolled, started 2009-02. Conditions recorded: Brain Cancer and Central Nervous System Diseases. Interventions recorded: DNX-2401 and Tumor Removal.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT00805376","url":"https://clinicaltrials.gov/study/NCT00805376"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["brain-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":["dnx-2401"],"companies":["dnatrix"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00805376","phase":"1","setting":"Phase I Trial of Conditionally Replication-Competent Adenovirus (DNX-2401, Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas","sponsor":"DNAtrix, Inc.","enrolled":37,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct00805376/","neighbours":{"cancer":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"}],"drug":[{"id":"dnx-2401","kind":"drug","name":"DNX-2401","route":"/drugs/dnx-2401/"}],"company":[{"id":"dnatrix","kind":"company","name":"DNAtrix","route":"/companies/dnatrix/"}]}}